SynthesisSeminars in arthritis and rheumatism2018
Pulmonary manifestations in late versus early systemic lupus erythematosus: A systematic review and meta-analysis.
Synthesis in Seminars in arthritis and rheumatism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Factors Associated with Systemic Lupus Erythematosus-Associated Interstitial Lung Disease and Clinical Outcomes: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Risk factors in systemic lupus erythematosus-associated Sjögren's syndrome: multicenter case-control studies and systematic review.Clinical rheumatology · 2025Pooled it
- Pulmonary diseases in SLE: a population-based cross-sectional study.Lupus science & medicine · 2026Article
- Early detection and risk stratification in autoimmune-related interstitial lung disease: a state-of-the-art review.Respiratory research · 2026Review
- Clinical and laboratory differences in characteristics of patients with early-onset and late-onset systemic lupus erythematosus: a single-center retrospective study.Reumatologia · 2026Article
- Unveiling the dual nature of late-onset systemic lupus erythematosus: A cross-sectional study.Rheumatology and immunology research · 2025Article
- Pulmonary Involvement in Systemic Lupus Erythematosus: A Potentially Overlooked Condition.Biomedicines · 2025Review
- Age-stratified risk factors and predictive models for progression to lupus nephritis in patients with systemic lupus erythematosus: a review.Frontiers in immunology · 2025Review
- Still's Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management.Drugs & aging · 2024Review
- The interplay between rheumatic diseases and pulmonary health.Rheumatology international · 2024Review
- Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?International journal of molecular sciences · 2023Review
- A Contemporary Update on the Diagnosis of Systemic Lupus Erythematosus.Clinical reviews in allergy & immunology · 2022Review
- An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management.Cureus · 2022Review
- Clinical and laboratorial outcome of different age-onset systemic lupus erythematosus patients in Jiangsu, China: a multicentre retrospective study.Scientific reports · 2022Article
- Systemic lupus erythematosus presenting with lymphoid interstitial pneumonia as an initial manifestation.BMJ case reports · 2021Article
- Endobronchial carcinoid presenting as Focal bronchiectasis in a young woman with systemic lupus erythematosus.Clinical case reports · 2021Article
- [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)].Zeitschrift fur Rheumatologie · 2021Article
- Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies.Trends in molecular medicine · 2021Review
- Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review.Therapeutic advances in musculoskeletal disease · 2021Review
- Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?Life sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesPhenotypes differ between late- and early-onset systemic lupus erythematosus (SLE). Prior studies suggested that there may be more pulmonary disease among late-onset patients. Our objective was to perform a systematic review and meta-analysis to evaluate the differences in pulmonary manifestations in late- versus early-onset SLE.
methodsWe searched the literature using PubMed, CINAHL, Web of Science, Cochrane Library, and EMBASE. We excluded studies that did not include American College of Rheumatology SLE classification criteria, an early-onset SLE comparison group, or those that defined late-onset SLE as <50 years of age. We rated study quality using the Newcastle-Ottawa Quality Scale. We used Forest plots to compare odds ratios (95% confidence intervals) of pulmonary manifestations by age. Study heterogeneity was assessed using I
resultsThirty-nine studies, representing 10,963 early-onset and 1656 late-onset patients with SLE, met eligibility criteria. The odds of developing several pulmonary manifestations were higher in the late-onset group. Interstitial lung disease (ILD) was nearly three times more common (OR = 2.56 (1.27, 5.16)). Pleuritis (OR = 1.53 (1.19, 1.96)) and serositis (OR = 1.31 (1.05, 1.65)) were also more common in the late-onset group. The mean Newcastle-Ottawa Quality Scale score for study quality was moderate (6.3 ± 0.7, scale 0-9).
conclusionsPulmonary manifestations of SLE were more common in late-onset SLE patients compared to their younger peers, in particular ILD and serositis. Age-related changes of the immune system, tobacco exposure, race, and possible overlap with Sjögren's syndrome should be examined in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.